<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889226</url>
  </required_header>
  <id_info>
    <org_study_id>CWP_PTV4_704</org_study_id>
    <nct_id>NCT00889226</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia</brief_title>
  <acronym>ESPRIT</acronym>
  <official_title>A Randomized, Open Label, Dose Titration Study to Evaluate the Efficacy and Safety of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open label, dose titration study to evaluate the efficacy and safety of
      Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of pitavastatin compared to atorvastatin on the change of Lipid
      profiles, ApoA1, ApoB, adiponectin and baPWV as a marker of atherosclerosis in Type 2DM .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving LDL- C＜100mg/dL</measure>
    <time_frame>After 16wk drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of LDL-C, TC, TG, HDL-C, Apo A1, Apo B</measure>
    <time_frame>After 16wk drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of hs-CRP 3</measure>
    <time_frame>After 16wk drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of fasting insulin</measure>
    <time_frame>After 16wk drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of adiponectin</measure>
    <time_frame>After 16wk drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of brachial ankle PWV</measure>
    <time_frame>After 16wk drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From enrollment to end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any abnormal change of physical examination and Lab result</measure>
    <time_frame>From enrollment to end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Hypercholesterolemia With Type2DM</condition>
  <arm_group>
    <arm_group_label>Pitavastatin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C &lt;100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks</description>
    <arm_group_label>Pitavastatin Group</arm_group_label>
    <other_name>Livalo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C &lt;100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks</description>
    <arm_group_label>Atorvastatin Group</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 25yrs~75yrs

          -  Fasting TG &lt;400mg/dL, LDL-C ≥130mg/dL

          -  3months &gt; Diagnosed Type2 DM, With OAD, HbA1c ≤ 10.0% or First Diagnosed Type2 DM,
             6.5%≤HbA1c≤10.0%

        Exclusion Criteria:

          -  Type1 DM, Gestational diabetes

          -  Patient need to treat with Insulin

          -  Patient with operational treatment for severe diabetic complication

          -  Uncontrolled Hypothyroidism

          -  Unstable angina, MI, transient ischemic attack(TIA), Stroke, PCI, Heart Failure within
             3 months (NYHA class4)

          -  Severe Hypertension (SBP ≥ 180 or DBP ≥ 110mmHg)

          -  Renal disorder (Serum creatinine ≥ 2.0mg/dL)

          -  Hepatic disorder (AST or ALT ≥ 2.5 X UNL)

          -  Creatinine Kinase &gt; 2.5 X UNL

          -  Gravida or lactation phase

          -  Administration of Atorvastatin, Rosuvastatin, Pitavastatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Young Shon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology, Kangnam Saint Mary's Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pitavastatin</keyword>
  <keyword>PWV</keyword>
  <keyword>ESPRIT</keyword>
  <keyword>Pitavastatin and Atorvastatin</keyword>
  <keyword>Adiponectin</keyword>
  <keyword>fasting insulin</keyword>
  <keyword>hs-CRP</keyword>
  <keyword>baPWV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

